Generic Name: ritonavir
Common side effects of Norvir include: asthenia, diarrhea, hypertriglyceridemia, increased gamma-glutamyl transferase, nausea, vomiting, and unpleasant taste. Other side effects include: abdominal pain, dyspepsia, fever, hyperlipidemia, increased serum alanine aminotransferase, peripheral paresthesia, dysgeusia, and oral paresthesia.  See below for a comprehensive list of adverse effects.
Applies to ritonavir: oral capsule liquid filled, oral solution, oral tablet
As well as its needed effects, ritonavir (the active ingredient contained in Norvir) may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking ritonavir, check with your doctor immediately:
Some ritonavir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to ritonavir: oral capsule, oral solution, oral tablet
The most frequently reported side effects associated with this drug alone and in combination with other antiretrovirals were gastrointestinal (including nausea, diarrhea, vomiting, upper and lower abdominal pain), neurological disturbances (including paresthesia, oral paresthesia), rash, and fatigue/asthenia.When used as a pharmacokinetic enhancer, side effects were dependent on the coadministered protease inhibitor.  The manufacturer product information for the coadministered protease inhibitor should be consulted.[Ref]
Pancreatitis (including some fatalities) has been reported in patients using this drug, including those who developed hypertriglyceridemia.Limit for high chemistry included amylase greater than 2 times the upper limit of normal (2 x ULN).[Ref]
Very common (10% or more): Diarrhea (including severe with electrolyte imbalance; up to 67.9%), nausea (up to 57.4%), vomiting (up to 31.9%), upper and lower abdominal pain (up to 26.4%), dyspepsia (up to 11.5%)Common (1% to 10%): Flatulence, gastrointestinal (GI) hemorrhage, gastroesophageal reflux disease, mouth ulcer, pancreatitis, increased amylase, constipation, circumoral paresthesia, local throat irritationFrequency not reported: Abnormal stools, bloody diarrhea, cheilitis, colitis, dry mouth, dysphagia, eructation, esophagitis, esophageal ulcer, fecal incontinence, gastritis, gastroenteritis, GI disorder, GI symptoms, gingivitis, ileitis, ileus, melena, oral moniliasis, periodontal abscess, pseudomembranous colitis, rectal disorder, rectal hemorrhage, sialadenitis, stomatitis, tenesmus, tongue edema, ulcerative colitis[Ref]
Very common (10% or more): Increased cholesterol (up to 65.2%), increased triglycerides (up to 33.6%)Common (1% to 10%): Increased fasting triglycerides, hypertriglyceridemia, increased uric acid, hypercholesterolemia, increased glucose, gout, dehydration, anorexia, increased alkaline phosphatase, decreased potassium, decreased calciumUncommon (0.1% to 1%): Diabetes mellitus, increased magnesium, increased LDH, increased chloride, increased potassium, decreased sodium, decreased chloride, decreased magnesiumRare (0.01% to 0.1%): HyperglycemiaFrequency not reported: Alcohol intolerance, avitaminosis, enzymatic abnormality, xanthomatosis, redistribution/accumulation of body fatAntiretroviral therapy:-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levelsProtease inhibitor therapy:-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis[Ref]
Limits for high chemistry included cholesterol greater than 240 mg/dL, triglycerides greater than 800 mg/dL, triglycerides greater than 1500 mg/dL (greater than 16.9 mmol/L), fasting triglycerides greater than 1500 mg/dL (greater than 16.9 mmol/L), uric acid greater than 12 mg/dL (greater than 0.7 mmol/L), glucose greater than 13.8 mmol/L, alkaline phosphatase greater than 550 units/L, LDH greater than 1170 units/L, chloride greater than 122 mmol/L, and potassium greater than 6 mmol/L.  Limits for low chemistry included potassium 3 mmol/L, calcium less than 3.45 mmol/L, chloride less than 84 mmol/L, magnesium less than 1 mmol/L, and sodium less than 123 mmol/L.Increases of 30% to 40% from baseline have been reported for cholesterol levels and 200% to 300% for triglycerides.Dehydration (usually associated with GI symptoms, and sometimes resulting in hypotension, syncope, or renal insufficiency) has been reported (including during postmarketing experience); orthostatic hypotension, syncope, and renal insufficiency have also been reported without known dehydration.Hyperglycemia has also been reported during postmarketing experience in patients with and without known history of diabetes.New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors; in some cases, diabetic ketoacidosis occurred.  No causal relationship has been established.[Ref]
Very common (10% or more): Paresthesia (including oral and peripheral paresthesia; up to 50.7%), dysgeusia (16.2%), dizziness (up to 15.6%), taste perversion (up to 15.5%), peripheral neuropathy (10.1%), headacheCommon (1% to 10%): Syncope, seizure, somnolenceFrequency not reported: Abnormal gait, amnesia, aphasia, ataxia, coma, convulsion, dementia, grand mal convulsion, hearing impairment, hyperesthesia, hyperkinesia, hypoesthesia, incoordination, migraine, neuralgia, neuropathy, paralysis, peripheral neuropathic pain, peripheral sensory neuropathy, sleep disorder, speech disorder, stupor, subdural hematoma, tinnitus, tremor, vertigo, vestibular disorder, cerebral ischemia, cerebral venous thrombosis, taste lossPostmarketing reports: Neurologic events[Ref]
Syncope and seizure have also been reported during postmarketing experience.Cardiac and neurologic events have been reported during postmarketing experience when this drug was used with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers.  Possible drug interaction could not be excluded.[Ref]
Very common (10% or more): Fatigue (including asthenia; 46.2%), asthenia (up to 14.2%), flushing/feeling hot (13.2%)Common (1% to 10%): Edema, peripheral edema, peripheral coldness, fever, weight loss, malaiseUncommon (0.1% to 1%): Decreased albuminFrequency not reported: Breast pain, enlarged abdomen, accidental injury, cachexia, chest pain, chills, facial edema, facial pain, influenza syndrome, hypothermia, neck pain, neck rigidity, pain (unspecified), pelvic pain, substernal chest pain, ear pain, increased cerumen, parosmia, thirstPostmarketing reports: Acute ergot toxicity (characterized by vasospasm, ischemia of extremities and other tissues [including the central nervous system])Antiretroviral therapy:-Frequency not reported: Increased weight[Ref]
Limit for low chemistry included albumin less than 20 g/L.Acute ergot toxicity has been reported when this drug was used with ergotamine or dihydroergotamine.[Ref]
Limits for low hematology included WBCs less than 2.5 x 10(9)/L, RBCs less than 3 x 10(12)/L, hematocrit less than 30% (less than 0.3), neutrophils up to 0.5 x 10(9)/L, hemoglobin less than 8 g/dL, and platelet count less than 2 x 10(9)/L.  Limits for high hematology included eosinophils greater than 1 x 10(9)/L, neutrophils greater than 20 x 10(9)/L, WBCs greater than 25 x 10(9)/L, and prothrombin time greater than 1.5 x ULN.Increased bleeding (including spontaneous skin hematomas and hemarthrosis) in patients with hemophilia type A or B treated has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.[Ref]
Very common (10% or more): Decreased WBCs (up to 36.9%), decreased RBCs (up to 18.6%), decreased hematocrit (up to 17.3%)Common (1% to 10%): Decreased neutrophils, decreased hemoglobin, thrombocytopenia, increased eosinophils, increased neutrophils, increased WBCsUncommon (0.1% to 1%): Increased prothrombin time, decreased platelet countFrequency not reported: Acute myeloblastic leukemia, anemia, ecchymosis, leukopenia, lymphadenopathy, lymphocytosis, myeloproliferative disorderProtease inhibitor therapy:-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs[Ref]
Toxic epidermal necrolysis has also been reported during postmarketing experience.Alopecia has been reported in patients using indinavir or atazanavir plus this drug.[Ref]
Very common (10% or more): Rash (including erythematous rash, maculopapular rash; up to 27.1%), pruritus (up to 12.2%)Common (1% to 10%): Acne, acquired lipodystrophy, sweatingRare (0.01% to 0.1%): Stevens-Johnson syndrome, toxic epidermal necrolysisFrequency not reported: Contact dermatitis, dry skin, eczema, erythema multiforme, exfoliative dermatitis, folliculitis, fungal dermatitis, furunculosis, maculopapular rash, molluscum contagiosum, onychomycosis, photosensitivity reaction, psoriasis, pustular rash, seborrhea, skin discoloration, skin disorder, skin hypertrophy, skin melanoma, urticaria, vesiculobullous rash, alopecia[Ref]
Very common (10% or more): Coughing (21.7%), oropharyngeal pain (15.9%), pharyngitisFrequency not reported: Asthma, bronchitis, increased cough, dyspnea, epistaxis, hiccup, hypoventilation, interstitial pneumonia, larynx edema, lung disorder, rhinitis, sinusitis[Ref]
Limits for high chemistry included GGT greater than 300 international units/L, AST greater than 180 international units/L, ALT greater than 215 international units/L, and total bilirubin greater than 61 mcmol/L.Hepatic dysfunction (including some fatalities) has been reported, generally in patients taking multiple concurrent medications and/or with advanced AIDS.[Ref]
Very common (10% or more): Increased GGT (up to 19.6%)Common (1% to 10%): Increased AST, increased ALT, hepatitis (including increased AST, ALT, GGT), increased blood bilirubin (including jaundice), increased total bilirubinFrequency not reported: Exacerbation of chronic liver disease, cholangitis, cholestatic jaundice, hepatic coma, hepatomegaly, hepatosplenomegaly, liver damage, liver function tests abnormal, hepatic transaminase elevations exceeding 5 x ULN, clinical hepatitis, jaundicePostmarketing reports: Hepatic dysfunction (including some fatalities)[Ref]
Very common (10% or more): Arthralgia and back pain (18.6%), increased creatine phosphokinase (CPK; up to 12.1%)Common (1% to 10%): Myalgia, myopathy/increased CPK, myositis, rhabdomyolysisFrequency not reported: Arthritis, arthrosis, bone disorder, bone pain, extraocular palsy, joint disorder, leg cramps, muscle cramps, muscle weakness, twitching, osteonecrosis[Ref]
Limit for high chemistry included CPK greater than 1000 international units/L.Osteonecrosis has been reported, particularly in patients with advanced HIV disease, long-term combination antiretroviral therapy, or other risk factors (including corticosteroid use, alcohol use, severe immunosuppression, higher body mass index).[Ref]
Common (1% to 10%): Hypersensitivity (including urticaria, face edema)Rare (0.01% to 0.1%): AnaphylaxisFrequency not reported: Allergic reactions (including urticaria, mild skin eruptions, bronchospasm, angioedema)[Ref]
Common (1% to 10%): Blurred visionFrequency not reported: Abnormal electrooculogram, abnormal electroretinogram, abnormal vision, amblyopia/blurred vision, blepharitis, conjunctivitis, diplopia, eye disorder, eye pain, iritis, photophobia, uveitis, visual field defect, vitreous disorder[Ref]
Common (1% to 10%): Increased urination, menorrhagiaFrequency not reported: Albuminuria, cystitis, dysuria, glycosuria, hematuria, impotence, nocturia, penis disorder, polyuria, urethritis, urinary frequency, urinary retention, urinary tract infection, vaginitis[Ref]
Menorrhagia has also been reported during postmarketing experience.[Ref]
Common (1% to 10%): Hypertension, hypotension (including orthostatic hypotension), vasodilationUncommon (0.1% to 1%): Myocardial infarctionFrequency not reported: PR interval prolonged, cardiovascular disorder, palpitation, peripheral vascular disorder, phlebitis, postural hypotension, tachycardia, vasospasm, hemorrhagePostmarketing reports: Orthostatic hypotension, first-degree atrioventricular (AV) block, second-degree AV block, third-degree AV block, right bundle branch block, cardiac events[Ref]
Myocardial infarction has also been reported during postmarketing experience.Cardiac and neurologic events have been reported during postmarketing experience when this drug was used with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers.  Possible drug interaction could not be excluded.[Ref]
Common (1% to 10%): Confusion, disturbance in attention, insomnia, anxiety, abnormal thinkingFrequency not reported: Abnormal dreams, depression, depersonalization, emotional lability, euphoria, agitation, hallucinations, decreased libido, manic reaction, nervousness, personality disorder
Common (1% to 10%): Renal impairment (e.g., oliguria, elevated creatinine)Uncommon (0.1% to 1%): Acute renal failure, increased creatinineFrequency not reported: Renal calculus, renal failure, abnormal kidney function, kidney pain, pyelonephritis, increased BUNPostmarketing reports: Renal insufficiency[Ref]
Limit for high chemistry included creatinine greater than 0.3 mmol/L.Renal insufficiency was reported in 3 AIDS patients receiving this drug.  All cases occurred within 10 to 15 days after starting this drug and all were reversible upon discontinuation.[Ref]
Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)
Cushing's syndrome and adrenal suppression have been reported when this drug was used with fluticasone or budesonide.[Ref]
Common (1% to 10%): Decreased free and total thyroxinFrequency not reported: Adrenal cortex insufficiency, hormone level alteredPostmarketing reports: Cushing's syndrome, adrenal suppression[Ref]
1. Ruane PJ,  Luber AD,  Wire MB, et al. "Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams fosamprenavir once daily in combination with either 100 OR 200 milligrams of ritonavir in healthy volunteers." Antimicrob Agents Chemother 51 (2006): 560-5
2. Aarnoutse RE,  Droste JA,  Van Oosterhout JJ, et al. "Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers." Br J Clin Pharmacol 55 (2003): 115-125
3. Brennan-Benson P,  Pakianathan M,  Rice P, et al. "Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta." AIDS 20 (2006): 297-9
4. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42
5. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL. 
6. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8
7. Michelet C,  Ruffault A,  Sebille V, et al. "Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients." Antimicrob Agents Chemother 45 (2001): 3393-402
8. Shelton MJ,  Wire MB,  Lou Y,  Adamkiewicz B,  Min SS "Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir." Antimicrob Agents Chemother 50 (2006): 928-34
9. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al "A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection." N Engl J Med 333 (1995): 1534-9
10. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22
11. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9
12. von Hentig N,  Muller A,  Rottmann C, et al. "Pharmacokinetics of saquinavir, atazanavir and ritonavir in a boosted double-protease inhibitor twice-daily regimen." Antimicrob Agents Chemother 51 (2007): 1431-9
13. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. Department of Health and
Human Services. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   (4/8/2015):
14. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al "A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group." N Engl J Med 333 (1995): 1528-33
15. AIDSinfo. NIH. National Institutes of Health "Guidelines for the Use of Antiretroviral Agents in
Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2016 Mar 1]):
16. Merry C, Barry M, Gibbons S, Mulcahy F, Back D "Improved tolerability of ritonavir derived from pharmacokinetic principles." Br J Clin Pharmacol 42 (1996): 787
17. Fontas E,  Van Leth F,  Sabin CA, et al. "Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?" J Infect Dis 189 (2004): 1056-74
18. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87
19. Fantoni M,  Del Borgo C,  Autore C "Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy." AIDS 17 Suppl 1 (2003): S162-9
20. Lee GA,  Rao M,  Mulligan K, et al. "Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers." AIDS 21 (2007): 2183-90
21. Dube M,  Fenton M "Lipid abnormalities." Clin Infect Dis 36(Suppl 2) (2003): S79-83
22. Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6
23. Brown CA,  Lesher JL Jr,  Peterson CM "Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia." J Am Acad Dermatol 52(5 Suppl 1) (2005): S86-9
24. Manfredi R, Calza L, Chiodo F "Gynecomastia associated with highly antiretroviral therapy." Ann Pharmacother 35 (2001): 438-9
25. Torres HA,  Barnett BJ,  Arduino RC "Alopecia associated with ritonavir-boosted atazanavir therapy." AIDS 21 (2007): 1391-1392
26. Lee D,  Benson CA,  Lewis CE,  Grunfeld C,  Scherzer R "Prevalence and factors associated with dry skin in HIV infection: the FRAM study." AIDS 21 (2007): 2051-2057
27. Ginarte M,  Losada E,  Prieto A,  Lorenzo-Zuniga V,  Toribio J "Generalized hair loss induced by indinavir plus ritonavir therapy." AIDS 16 (2002): 1695-6
28. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89
29. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
30. Schrooten W,  Colebunders R,  Youle M, et al. "Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment." AIDS 15 (2001): 1019-23
31. Duong M, Sgro C, Grappin M, Biron F, Boibieux A "Renal failure after treatment with ritonavir." Lancet 348 (1996): 693-4
32. Chugh S, Bird R, Alexander EA "Ritonavir and renal failure." N Engl J Med 336 (1997): 138
33. Barbour TD,  Furlong TJ,  Finlayson RJ "Efavirenz-associated podocyte damage." AIDS 21 (2007): 257-258
34. Izzedine H,  Launay-Vacher V,  Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17
35. Roling J,  Schmid H,  Fischereder M,  Draenert R,  Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95
It is possible that some side effects of Norvir may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Fainting
feeling faint, dizzy, or lightheaded
feeling of warmth or heat
flushing or redness of the skin, especially on the face and neck
headache
sweating


Confusion
dehydration
dry or itchy skin
fruity mouth odor
increased hunger
increased thirst
increased urination
nausea
vomiting
weight loss


Bloating
chills
constipation
convulsions
cough
darkened urine
decreased urination
difficulty with breathing
dry mouth
fast heartbeat
fever
hives or welts, itching, or skin rash
increase in heart rate
indigestion
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
loss of appetite
loss of bladder control
muscle spasm or jerking of all extremities
noisy breathing
pains in the stomach, side, or abdomen, possibly radiating to the back
rapid breathing
redness of the skin
sudden loss of consciousness
sunken eyes
thirst
tightness in the chest
unusual tiredness or weakness
wrinkled skin
yellow eyes or skin


Acid or sour stomach
belching
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
change in sense of taste
diarrhea
dizziness
general feeling of discomfort or illness
heartburn
lack or loss of strength
sleepiness or unusual drowsiness
trouble sleeping
weakness


Body aches or pain
congestion
delusions
dementia
difficulty with moving
discouragement
dryness or soreness of the throat
excess air or gas in the stomach or intestines
fear
feeling sad or empty
full feeling
hoarseness
increased urge to urinate during the night
irritability
lack of appetite
loss of interest or pleasure
mood or mental changes
muscle pain or stiffness
nervousness
pain in the joints or in unspecified location
passing gas
runny nose
tender, swollen glands in the neck
throat irritation
tiredness
trouble concentrating
trouble swallowing
voice changes
waking to urinate at night


Gaining weight around your neck, upper back, breast, face, or waist

